ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Gamal, Nesrine; Vitale, Giovanni; Andreone, Pietro
• Is Part Of: Expert review of anti-infective therapy. Volume 13:Issue 3(2015)
• Page Start: 295
• Page End: 304
• Publication Date: 2015-03
• Subjects: Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1586/14787210.2015.1001746
• Languages: English
• ISSNs: 1478-7210

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Chronic hepatitis C (CHC) constitutes a major health concern. Hepatitis C virus eradication by antiviral treatment can markedly reduce the risk of developing cirrhosis, hepatocellular carcinoma and liver-related death. A plethora of new direct antiviral agents have been developed and are being explored in clinical trials. One of the newest members of this family is the NS3/4A protease inhibitor ABT-450. The multi-targeted approach combining ritonavir-enhanced ABT-450 with ombitasvir and dasabuvir has been evaluated for the treatment of CHC Gt1 in treatment-naïve and treatment-experienced adults. In this article, we sought to discuss the current knowledge on ABT-450-containing regimens, with special emphasis on treatment-experienced CHC Gt1 patients. This new combination was found to be potent, safe and well tolerated. Future Phase III trials with larger sample size in patients with decompensated cirrhosis, non-Gt1, end-stage renal disease and liver transplant recipients are eagerly awaited.</p> </abstract>